Can it get any worse for Novartis’ U.S. stock? The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. The drugmaker’s U.S.-listed shares slumped 13% to $139.01 Tuesday.
Markets
September 12, 2026
Novartis: More Pain on the Way?
A
By admin
A
admin
app staff editors and correspondents provide up-to-the-minute analysis on market mechanics, corporate actions, and global economic shifts.
No comments yet. Be the first to start the discussion!